Sign in

    Mckesson Corp (MCK)

    You might also like

    McKesson Corporation is a leading healthcare services and information technology company that operates through four main segments, focusing on the distribution of pharmaceutical and medical products, which account for the majority of its revenues . The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and healthcare-related products in the United States, and provides practice management, technology, clinical support, and business solutions to specialty practices . McKesson also addresses medication access and affordability challenges, offers medical-surgical supply distribution, and operates internationally in Canada and Europe .

    1. U.S. Pharmaceutical - Distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the United States, and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices .
    2. Prescription Technology Solutions (RxTS) - Addresses medication access, affordability, and adherence challenges by connecting patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies, offering prescription price transparency, benefit insight, dispensing support services, and third-party logistics .
    3. Medical-Surgical Solutions - Provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies, offering national brand medical-surgical products and McKesson's own line of products .
    4. International - Includes operations in Canada and Europe, providing non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services, with Canadian operations delivering medicines, supplies, and information technology solutions, and European operations focusing on distribution and services in Norway .
    NamePositionStart DateShort Bio
    Brian S. TylerChief Executive OfficerApril 2019Brian S. Tyler has served as the Chief Executive Officer of McKesson Corporation since April 2019. He has held various leadership positions within McKesson and has over 25 years of business and healthcare experience .
    Britt J. VitaloneExecutive Vice President and Chief Financial OfficerJanuary 2018Britt J. Vitalone has been serving as the Executive Vice President and Chief Financial Officer of McKesson Corporation since January 2018. He has been with the company for 17 years as of the fiscal year 2023 .
    Michele LauExecutive Vice President and Chief Legal OfficerJanuary 1, 2024Michele Lau is the Executive Vice President and Chief Legal Officer at McKesson Corporation, a position she will hold starting January 1, 2024. She previously served as the Chief Legal Officer at GoDaddy .
    LeAnn B. SmithExecutive Vice President and Chief Human Resources OfficerDecember 2022LeAnn B. Smith is the Executive Vice President and Chief Human Resources Officer at McKesson Corporation since December 2022. She previously worked at Walmart Inc. as the Chief People Leader for Global Corporate Functions .
    Thomas L. RodgersExecutive Vice President and Chief Strategy and Business Development OfficerJune 2020Thomas L. Rodgers has been serving as the Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation since June 2020. He was previously the Senior Vice President and Managing Director of McKesson Ventures .
    1. With the acquisition of Rx Savings Solutions aiming to provide price transparency to employers and employees, how does McKesson plan to leverage this capability to impact drug pricing or influence drug utilization patterns, and what is the long-term strategic vision for integrating this asset into your overall strategy?
    2. Given the evolving landscape of U.S. retail pharmacies and the closures of many stores, would McKesson consider changing its domestic strategy by owning a virtual pharmacy to capitalize on emerging opportunities, despite previous beliefs about customer conflict and operational challenges?
    3. As oncology care shifts towards value-based models, how is McKesson adapting its services to support providers in this transition, and what specific initiatives or partnerships are you pursuing to facilitate success in value-based oncology care?
    4. In light of competitive pressures from companies serving both acute care facilities and alternate sites, especially with large integrated delivery networks (IDNs) owning both assets, how does McKesson plan to address potential market changes and growth opportunities, and is there a need to rethink your approach to the medical distribution market?
    5. Considering your expansion into specialties like retina and ophthalmology through acquisitions, does McKesson have plans to build comprehensive platforms in other specialty areas similar to your oncology platform, and how do you evaluate the potential for achieving similar success outside of oncology?
    Program DetailsProgram 1
    Approval DateJuly 2024
    End Date/DurationN/A
    Total additional amount$4.0 billion
    Remaining authorization amount$8.6 billion
    DetailsThe Board approved an increase in the authorization for the repurchase of common stock.
    YearAmount Due (in millions)Debt TypeInterest Rate% of Total Debt
    2025$1,167 0.90% U.S. Dollar Notes, 1.50% Euro Notes 0.90%, 1.50% 20.3% = (1,167 / 5,744) * 100
    2026$1,055 1.30% U.S. Dollar Notes, 1.63% Euro Notes 1.30%, 1.63% 18.4% = (1,055 / 5,744) * 100
    2027$150 7.65% U.S. Dollar Debentures 7.65% 2.6% = (150 / 5,744) * 100
    2028$742 3.95% U.S. Dollar Notes, 4.90% U.S. Dollar Notes 3.95%, 4.90% 12.9% = (742 / 5,744) * 100
    2029$1,298 4.75% U.S. Dollar Notes, 4.25% U.S. Dollar Notes, 3.13% Sterling Notes 4.75%, 4.25%, 3.13% 22.6% = (1,298 / 5,744) * 100
    2033$597 5.10% U.S. Dollar Notes 5.10% 10.4% = (597 / 5,744) * 100
    2041$218 6.00% U.S. Dollar Notes 6.00% 3.8% = (218 / 5,744) * 100
    2044$255 4.88% U.S. Dollar Notes 4.88% 4.4% = (255 / 5,744) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Cencora, Inc. - Mentioned as one of the largest competitors in distribution, wholesaling, and logistics .
    • Cardinal Health, Inc. - Mentioned as one of the largest competitors in distribution, wholesaling, and logistics .
    CustomerRelationshipSegmentDetails
    CVS Health Corporation
    Pharmaceutical distribution partner; extended to June 2027.
    All
    Revenue: 28% of total consolidated revenues ($308,951 million) = $86,506 million.<br>Accounts Receivable: 24% of net trade accounts receivable ($21,622 million) = $5,189 million.
    NameStart DateEnd DateReason for Change
    Deloitte & Touche LLPMay 7, 2024 PresentCurrent auditor